AGX-148

N/A

Report date: 2026/04/17 10:36:33

Base Information

Drug NameAGX-148
Drug Alias NameCD39+CD103+CD8+ Tumor-isolated T CellsSelected CD39+CD103+CD8+ ATCAGX-148AGX148
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionT lymphocyte replacementsAnti-Ectonucleoside triphosphate diphosphohydrolase 1Cluster of differentiation 8 modulators
TargetsEctonucleoside triphosphate diphosphohydrolase 1Cluster of differentiation 8
Therapy Area/IndicationsGenital Neoplasms, FemaleUrogenital NeoplasmsLung Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAgonOx Inc
China Registration ClassN/A

Develop Information

Active CompaniesAgonOx Inc
Inactive CompaniesN/A
Active IndicationsGenital Neoplasms, FemaleUrogenital NeoplasmsLung Neoplasms +[6] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A